Abstract：Objective To analyze whether involved-field irradiation (IFI) was associated with improved survival and reduced treatment-related adverse events compared with elective nodal irradiation (ENI) in Chinese patients with esophageal squamous cell carcinoma receiving radiotherapy. Methods Literature review was conducted from CNKI, Wanfang Data, PubMed, Embase, Web of Science and Cochrane Central databases (until July 31, 2022). Relevant data were collected according to the inclusion and exclusion criteria. Primary outcomes included overall survival (OS) rate and treatment-related adverse events. Secondary outcomes included progression-free survival (PFS) rate and local control rate (LCR). Risk of bias was assessed using the Cochrane Risk of Bias tool. The quality of the results was assessed by using the meta analysis of Evidence Evaluation and Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methods. Results A total of 7 articles with 918 patients were included of which 465 received IFI and 453 received ENI. The 1-, 2-, 3-and 5-year OS rates in the IFI group were not significantly different from those in the ENI group (1-year OS rate: RR=1.00, 95%CI=0.94-1.07, P=0.97, high certainty; 2-year OS rate: RR=1.01, 95%CI=0.90-1.13, P=0.90, high certainty; 3-year OS rate: RR=0.86, 95%CI=0.71-1.05, P=0.14, high certainty; 5-year OS rate: RR=0.76, 95%CI=0.42-1.37, P=0.36, low certainty). In the IFI group, patients with ≥grade 2 acute radiation esophagitis (RR=0.71, 95%CI=0.58-0.87, P=0.001, high certainty), ≥grade 3 acute radiation esophagitis (RR=0.39, 95%CI=0.24-0.64, P<0.001, high certainty) and ≥grade 2 acute radiation pneumonitis (RR=0.72, 95%CI=0.52-0.99, P=0.04, high certainty) were significantly lower compared with those in the ENI group. However, no significant differences were observed in the incidence of ≥grade 3 late radiation esophagitis, ≥grade 3 acute radiation pneumonitis and ≥grade 3 late radiation pneumonitis between two groups. No significant differences were noted in the 1-, 2-, 3-PFS rates and LCR between two groups. Conclusions For Chinese patients with esophageal squamous cell carcinoma, IFI and ENI yield similar efficacy in terms of OS, PFS and LCR. However, IFI has a lower incidence of ≥grade 2 acute radiation esophagitis, ≥grade 3 acute radiation esophagitis and ≥grade 2 acute radiation pneumonitis than ENI.
Wang Hesong,Song Chunyang,Zhao Xiaohan et al. Involved-field irradiation and elective nodal irradiation for esophageal squamous cell carcinoma: a systematic review and meta-analysis[J]. Chinese Journal of Radiation Oncology, 2023, 32(6): 512-518.
[1] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132. DOI: 10.3322/caac.21338. [2] Enzinger PC, Mayer RJ.Esophageal cancer[J]. N Engl J Med, 2003,349(23):2241-2252. DOI: 10.1056/NEJMra035010. [3] Paul S, Altorki N.Outcomes in the management of esophageal cancer[J]. J Surg Oncol, 2014,110(5):599-610. DOI: 10.1002/jso.23759. [4] Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. JAMA,1999,281(17):1623-1627. DOI: 10.1001/jama.281.17.1623. [5] Fokas E, Rödel C. Definitive, Preoperative,palliative radiation therapy of esophageal cancer[J]. Viszeralmedizin, 2015,31(5):347-353. DOI: 10.1159/000440638. [6] Zhu HC, Rivin Del Campo E, Ye JJ, et al. Involved-field irradiation in definitive chemoradiotherapy for locoregional esophageal squamous cell carcinoma: results from the ESO-Shanghai 1 trial[J]. Int J Radiat Oncol Biol Phys, 2021,110(5):1396-1406. DOI: 10.1016/j.ijrobp.2021.02.053. [7] Tsuruoka S, Kataoka M, Makita K, et al.EP-1435: the role of elective nodal irradiation in radiotherapy for stage I esophageal cancer[J]. Radiother Oncol,2018,127: S780. DOI:10.1016/S0167-8140(18)31744-4. [8] Li M, Zhao F, Zhang X, et al.Involved-field irradiation in definitive chemoradiotherapy for T4 squamous cell carcinoma of the esophagus[J]. Curr Oncol, 2016,23(2):e131-137. DOI: 10.3747/co.23.2846. [9] Kono S, Ishii Y, Matsubara H, et al.Is involved-field irradiation sufficient for superficial esophageal carcinoma?[J]. Int J Radiat Oncol Biol Phys,2016,96(2):E162. DOI:10.1016/j.ijrobp.2016.06.998. [10] Sekii S, Ito Y, Kato K, et al.Recurrence pattern after definitive chemoradiation therapy for cervical esophageal cancer[J]. Int J Radiat Oncol Biol Phys,2015,93(3):E158. DOI:10.1016/j.ijrobp.2015.07.953. [11] Jean-Mary E, Dalban C, Serre AA, et al. Elective nodal irradiation during exclusive chemoradiation for locally-advanced esophageal cancer: IMRT better spares critical organs at risk[J]. Eur J Cancer,2015,51:S351. DOI:10.1016/S0959-8049(16)30992-3. [12] Nishibuchi I, Murakami Y, Adachi Y, et al.Long-term results of definitive chemoradiotherapy with elective nodal irradiation using modern radiotherapy technique for resectable locally advanced esophageal cancer[J]. Int J Radiat Oncol Biol Phys,2019, 105(1): E193. DOI: 10.1016/j.ijrobp.2019.06.2110. [13] Lee DY, Moon SH, Cho KH, et al.Treatment outcomes of extended-field radiation therapy for thoracic superficial esophageal cancer[J]. Radiat Oncol J, 2017,35(3):241-248. DOI: 10.3857/roj.2017.00458. [14] Xie CQ, Jing Z, Luo HL, et al.Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial[J]. Br J Cancer, 2020,123(11):1616-1624. DOI: 10.1038/s41416-020-01054-6. [15] Li B, Zhang J, Zhang K, et al. Chemoradiation with ENI versus IFI, high-dose versus standard-dose radiation therapy for locally advanced esophageal squamous cell carcinoma: preliminary results of multicenter, phase III clinical trial (NROG 001-Northern Radiation Oncology Group of China)[J]. Int J Radiat Oncol Biol Phys,2019,105(1):E188-E189. DOI:10.1016/j.ijrobp.2019.06.2096. [16] 吕家华, 伊斯刊达尔·阿布力米提, 李涛, 等. 胸段食管鳞癌根治性放化疗IFI和ENI前瞻性多中心随机对照临床研究[J].中华放射肿瘤学杂志,2018,27(3):245-249. DOI: 10.3760/cma.j.issn.1004-4221.2018.03.004. Lyu JH,Yisikandaer·Abulimiti, Li T, et al. Involved field irradiation (IFI) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for esophageal thoracic squamous cell cancer: a prospective, randomized, multicenter, controlled study[J].Chin J Radiat Oncol,2018,27(3):245-249. DOI: 10.3760/cma.j.issn.1004-4221.2018.03.004. [17] 阿不力克木江·阿地力, 王海峰, 伊斯刊达尔·阿布力米提, 等. 选择性淋巴结区域照射和累及野照射治疗胸段食管癌患者的临床观察[J].天津医药,2018,46(2):161-165. DOI: 10.11958/20171072. Abulikemujiang·Adili, Wang HF, Yisikandaer·Abulimiti, et al. Clinical observation on the thoracic esophageal cancer patients treated with elective nodal irradiation and involved field irradiation[J].Tianjin Medical Journal,2018,46(2):161-165. DOI: 10.11958/20171072. [18] 臧茹琨, 马金波, 宋轶鹏, 等.中胸段食管癌累及野与淋巴结选择性照射对比研究[J].中华肿瘤防治杂志,2013,20(24):1917-1920.DOI:10.16073/j.cnki.cjcpt.2013.24.016. Zang RK, Ma JB, Song YP, et al.Comparation of involved-field conformal irradiation and elective nodal irradiation for middle-thoracic esophageal cancer[J]. Chin J Cancer Prev Treat,2013,20(24):1917-1920.DOI:10.16073/j.cnki.cjcpt.2013.24.016. [19] 李曼, 乔学英, 周志国, 等.胸段食管癌三维适形放疗临床靶体积前瞻性随机临床研究[J].中国肿瘤临床,2012,39(17):1294-1298. Li M, Qiao XY, Zhou ZG, et al.A prospectively randomized study of clinical target volume margins for three-dimensional conformal radiotherapy in patients with thoracic esophageal squamous cell carcinoma[J]. Chin J Clin Oncol,2012,39(17):1294-1298. [20] Ma JB, Song YP, Yu JM, et al.Feasibility of involved-field conformal radiotherapy for cervical and upper-thoracic esophageal cancer[J]. Onkologie, 2011,34(11):599-604. DOI: 10.1159/000334194. [21] Zhu HP, Pan W, Chen Y, et al.What is the optimal radiotherapy target size for non-operable esophageal cancer? A meta-analysis[J]. Oncol Res Treat, 2019,42(9):470-479. DOI: 10.1159/000501594. [22] 王利利, 王坚, 于波,等.老年食管癌放疗毒副作用和预后相关因素分析[J].中华肿瘤防治杂志,2018,25(23):1638-1642.DOI:10.16073/j.cnki.cjcpt.2018.23.005. Wang LL, Wang J, Yu B, et al. Analysis of side effects and prognosis of radiotherapy alone in treatment of senile esophageal cancer[J]. Chin J Cancer Prev Treat,2018,25(23):1638-1642. DOI:10.16073/j.cnki.cjcpt.2018.23.005. [23] Sun Y, Zhang XL, Mao QF, et al.Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients[J]. Curr Oncol, 2018,25(5):e423-e429. DOI: 10.3747/co.25.3895. [24] Su J, Zhu S, Liu Z, et al.Target volume delineation for radical radiotherapy of early oesophageal carcinoma in elderly patients[J]. Cancer Radiother, 2017,21(1):34-39. DOI: 10.1016/j.canrad.2016.08.129. [25] Li DJ, Li HW, He B, et al.Patterns of failure after involved field radiotherapy for locally advanced esophageal squamous cell carcinoma[J]. J BUON, 2016,21(5):1268-1273. [26] 白文文, 宋玉芝, 刘明,等.SIB-IMRT技术在颈及胸上段食管癌中的临床应用[J].中华肿瘤防治杂志,2016,23(4):248-252.DOI:10.16073/j.cnki.cjcpt.2016.04.010. Bai WW, Song YZ, Liu M, et al.Clinical application of simultaneous integrated boost intensity-modulated radiation therapy in cervical and upper esophageal carcinoma[J]. Chin J Cancer Prev Treat,2016, 23(4):248-252.DOI:10.16073/j.cnki.cjcpt.2016.04.010. [27] Jing W, Zhu H, Guo HB, et al.Feasibility of elective nodal irradiation (ENI) and involved field irradiation (IFI) in radiotherapy for the elderly patients (aged ≥ 70 years) with esophageal squamous cell cancer: a retrospective analysis from a single institute[J]. PLoS One, 2015,10(12):e0143007. DOI: 10.1371/journal.pone.0143007. [28] Zhu S, Su J, Liu Z, et al. Comparative study of the failure model of esophageal cancer with elective nodal prophylactic and involved-field irradiation [J]. Int J Radiat Oncol Biol Phys,2015,93(3): E142-E143.DOI: 10.1016/j.ijrobp.2015.07.911. [29] 沈文斌, 高红梅, 祝淑钗, 等.临床早期食管癌选择性淋巴结照射与累及野照射的初步比较[J].中国肿瘤临床,2013,40(17):1047-1050. Shen WB, Gao HM, Zhu SC, et al. Preliminary comparative study between elective nodal irradiation and involved field radiation therapy for clinical early-stage esophageal carcinoma[J]. Chin J Clin Oncol,2013,40(17): 1047-1050. [30] 谢国栋, 蔡晶. 颈胸上段食管癌锁骨上预防照射93例分析[J].南通医学院学报,2000,(3):269. Xie GD, Cai J.Analysis of 93 cases of supraclavicular prophylactic irradiation for upper cervicothoracic esophageal cancer[J]. Journal of Nantong Medical College,2000,(3):269. [31] Zhu SC, Li QF, Zhang XY, et al.[Clinical outcomes of different irradiation ranges in definitive intensity- modulated radiotherapy for esophageal cancer][J]. Zhonghua Zhong Liu Za Zhi, 2020,42(12):1040-1047. DOI: 10.3760/cma.j.cn112152-20191225-00842. [32] Jing Z, Chen T, Zhang XB, et al.Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer[J]. Cancer Sci, 2017,108(9):1828-1833. DOI: 10.1111/cas.13308. [33] Park JH, Kim WC, Kim HJ. Comparison of the treatment results of involved-field and elective nodal irradiation in locally advanced esophageal cancer [J]. Esophagus,2016,13(4): 361-368. [34] 车俊, 张福正, 邹勤舟, 等. 选择性淋巴引流区照射与累及野照射联合化疗治疗食管癌效果分析[J].肿瘤研究与临床,2022,34(4):271-275. DOI: 10.3760/cma.j.cn115355-20211103-00493. Che J, Zhang FZ, Zou QZ, et al.Efficacy analysis of elective nodal irradiation and involved field irradiation combined with chemotherapy in treatment of esophageal cancer[J].Cancer Res Clin,2022,34(4):271-275. DOI: 10.3760/cma.j.cn115355-20211103-00493. [35] 曾国沐, 王婷婷. 累及野照射与选择性淋巴引流区照射治疗高龄食管癌的效果及其预后影响因素[J].中外医学研究,2021,19(23):5-7. DOI: 10.14033/j.cnki.cfmr.2021.23.002. Zeng GM, Wang TT.Efficacy and prognostic factors of involved field irradiation and elective lymphatic drainage irradiation in the treatment of elderly esophageal cancer[J]. Chinese and Foreign Medical Research,2021,19(23):5-7. DOI: 10.14033/j.cnki.cfmr.2021.23.002. [36] 姚钧, 孙小兵. 食管癌三维适形放疗淋巴引流区预防照射与累及野照射疗效比较[J].山东医药,2015,(14):94-95. DOI: 10.3969/j.issn.1002-266X.2015.14.037. Yao J, Sun XB. Comparison of the efficacy of preventive versus involved field irradiation in the lymphatic drainage area of three-dimensional conformal radiotherapy for oesophageal cancer[J]. Shandong Medicine,2015,(14): 94-95. DOI: 10.3969/j.issn.1002-266X.2015.14.037. [37] 杨军, 冯婷婷, 杨庆辉, 等. 局部晚期食管鳞癌累及野与预防性照射同步放化疗效果观察[J].社区医学杂志,2022,20(6):314-318. DOI: 10.19790/j.cnki.JCM.2022.06.04. Yang J, Feng TT, Yang QH, et al.Comparative analysis of the curative effect and adverse reactions of prophylactic chemoradiotherapy in involved fields in patients with locally advanced esophageal squamous cell cancer[J].J Community Med,2022,20(6):314-318. DOI: 10.19790/j.cnki.JCM.2022.06.04. [38] Cheng YJ, Jing SW, Zhu LL, et al.Comparison of elective nodal irradiation and involved-field irradiation in esophageal squamous cell carcinoma: a meta-analysis[J]. J Radiat Res, 2018,59(5):604-615. DOI: 10.1093/jrr/rry055. [39] 李萌, 王太芳, 吴春丽, 等. 淋巴结累及野照射与预防野照射对亚洲人群食管癌放疗效果比较的Meta分析[J].肿瘤研究与临床,2019,31(4):262-268. DOI: 10.3760/cma.j.issn.1006-9801.2019.04.011. Li M, Wang TF, Wu CL, et al.Efficacy comparison of lymph node involved-field irradiation and elective nodal irradiation for treatment of esophageal cancer among Asian populations:a meta analysis[J].Cancer Res Clin,2019,31(4):262-268. DOI: 10.3760/cma.j.issn.1006-9801.2019.04.011. [40] Li QF, Zhu SC, Li SG, et al.Elective nodal irradiation provides a superior therapeutic modality for lymph node positivity esophageal squamous cell carcinoma patients receiving definitive radiotherapy versus involved-field irradiation[J]. Medicine (Baltimore), 2019,98(3):e14080. DOI: 10.1097/MD.0000000000014080. [41] Li SQ, Pan XF, Kashaf MS, et al.Five-year survival is not a useful measure for cancer control in the population: an analysis based on UK data[J]. Asian Pac J Cancer Prev, 2017,18(2):571-576. DOI: 10.22034/APJCP.2017.18.2.571. [42] Morgans AK, van Bommel AC, Stowell C, et al. Development of a standardized set of patient-centered outcomes for advanced prostate cancer: an international effort for a unified approach[J]. Eur Urol, 2015,68(5):891-898. DOI: 10.1016/j.eururo.2015.06.007. [43] Wang XY, Miao CW, Chen Z, et al.Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis[J]. Onco Targets Ther, 2017,10:2087-2095. DOI: 10.2147/OTT.S130285.
2023, Vol. 32 
